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injury. It induces severe clinical maternal hypertension and proteinuria. 1 It has been reported that PE affects 2%-8% of pregnancies worldwide. 2 When severe, uncontrolled symptoms of the disorder can result in significant morbidity and mortality of both mother and foetus. As would be expected, the disease induces a series of typical complications, including refractory hypertension, kidney damage and acute pulmonary oedema. 3 Currently, preventative measures for the disorder include aspirin therapy, low-intake calcium supplementation and treatment of prior hypertension with medication. 2, 4, 5 .
Despite these efforts, delivery of the baby and placenta remains the most effective treatment for patients with PE. 6, 7 Though recent developments have improved its treatment, the disease mechanism still remains unclear. It has been reported that tissue factor pathway inhibitor 2 (TFPI2) may play a role in numerous biological behaviours, such as cell proliferation, differentiation and apoptosis. [8] [9] [10] As a suppressor gene, TFPI2 is known to be dysregulated in multiple human disorders, including PE 11 and various cancers. Altogether, miRNAs are known to be involved in many pathological and physiological processes, such as cellular growth, organogenesis, invasion, migration and apoptosis. 17 The accumulated evidence suggests that the analysis of miRNAs will prove to be useful in studying a variety of diseases, ranging from diabetes 18 to tumourgenesis. 19, 20 Also, the study of miRNAs has expedited technological advancements in RNA-based treatments. MiRNAs are now being studied for their potential as next-generation drugs. A study of the miRNA expression profile in placentas of PE patients explored many PE-associated, differentially expressed miRNAs.
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To date, several studies have also revealed that miRNAs play a specific role in placental development and that more miRNAs could be candidates for biomarkers in early screening of PE. [22] [23] [24] In this report, we established that the level of TFPI2 was significantly upregulated in PE placental tissues compared with that in normal tissues. Furthermore, knockdown of TFPI2 promoted cell growth and migration in trophoblast cell lines. Mechanistic investigation revealed that miR-616-3p binds to the 3′-UTR region of wildtype TFPI2 mRNA in cytoplasm. Therefore, our findings show an miR-616-3p-TFPI2-associated mechanism in PE, thus providing novel insights for the development of clinical predictive analytics, molecular diagnostics and targeted therapy for future PE treatments.
| MATERIAL SANDME THODS

| TissuecollectandEthicsstatement
Study participants were PE patients from the obstetrical department of the First Affiliated Hospital of Nanjing Medical University.
Written informed consent was provided by all participants. This study was approved by the Ethics Board of the First Affiliated
Hospital of Nanjing Medical University, China, and it was performed in compliance with the Declaration of Helsinki Principles. in RPMI 1640 (GIBCO, Nanjing, China) and MEM (GIBCO, Nanjing, China), respectively, to which we added 10% FBS (GIBCO, Invitrogen, Carlsbad, CA, USA) and 1% penicillin/streptomycin (Invitrogen). 
| Celllineandculture
| Celltransfection
| Plasmidconstruction
To ectopically upregulate TFPI2 expression, TFPI2 plasmid (2444 bp, NM_006528.3, synthesized by Realgene, Nanjing, China) was subcloned into pcDNA3.1(+) vector (Invitrogen), following standard protocols. TFPI2 plasmids as well as empty vector were transfected into HTR-8/SVneo on 6-well plates and/or 24-well plates.
| RNAextractionandqRT-PCRanalyses
RNA extraction and qRT-PCR assays were performed as previously reported in Xu et al 25 Total RNA from tissues and cells was extracted by using the TRIzol reagent (Invitrogen) and qRT-PCR analyses were performed by using the SYBR ® Green Master Mix (TaKaRa BIO INC, Otsu, Japan) following standard protocols. Results were normalized to the level of GAPDH. For miRNA quantification, miScript reverse transcription kit (Q iagen, Valencia, CA, USA) was used to reverse transcribe miRNA into cDNA. Primers for miR-616-3p and U6 were purchased from GeneCopoeia (Rockville, MD, USA). Gene-specific primers sequences were as follows: TFPI2 Forward-1 5′-CTGGGGCTGTCGATTCTGC-3′
Reverse-1 5′-TCTCCGCGTTATTTCCTGTTG-3′; Forward-2 5′-CA GATGAAGCTACTTGTATGGGCTTC-3′ Reverse-2 5′-GGCAAAGCGA AGCTTTGGCATC-3′; Forward-3 5′-CTGGGGCTGTCGATTCTGC-3′
Reverse-3 5′-TCTCCGCGTTATTTCCTGTTG-3′; GAPDH Forward 5′-G GGAGCCAAAAGGGTCAT-3′ Reverse 5′-GAGTCCTTCCACGATACC AA-3′; U6 Forward 5′-CTCGCTTCGGCAGCACA-3′ Reverse 5′-AAC GCTTCACGAATTTGCGT-3′. cDNA was amplified on a 7500 RealTime PCR System (7500, Applied Biosystems, Foster City, CA, USA)
with SYBR Premix Ex Taq (Takara, Dalian China).
| Cellviabilityassays
To assess the cell growth ability of HTR-8/SVneo and JEG3 cell lines, MTT and EdU assays were conducted. These experiments were carried out as previously reported. 25 For the MTT assays, 
| Quantitativecellmigrationassays
This experiment was carried out as previously described. 26 Briefly, HTR-8/SVneo and JEG3 cell lines, transfected with specific siRNAs and/or plasmid, were re-suspended in RPMI 1640 containing 1% FBS and then added to the upper chamber. The lower chamber was filled with 700 μL RPMI 1640 containing 10% FBS. After incubation for 24 hours at 37°C, cells inside the upper chamber were removed before fixing. Cells on the bottom membrane surface were fixed with methanol and then stained with a 0.5% crystal violet solution. Three to five randomly dispersed fields were counted per well.
| Westernblottinganalysis
These assays were performed to detect protein levels as previously described in Xu et al. 26 Five to 15 μL of each sample was loaded onto a 10% SDS gel, then analysed by western blotting. The samples were incubated with specific antibodies (GAPDH, TFPI2, E-cadherin, N-cadherin and vimentin, purchased from CST or Proteintech) at 1:1000 concentration. GAPDH was used as a loading control. The intensity of autoradiogram protein bands was quantified using Quantity One software (Bio-Rad, Hercules, CA, USA).
| Luciferasereporterassays
The complementary DNA fragment containing the wild-type and mutant TFPI2 3′-UTR was linked into the pGL3-basic vector (Promega).
HTR-8/SVneo cells were co-transfected with either the wild-type or mutant 3′-UTR of the TFPI2 vector, along with a miR-616-3p mimic or miR-616-3p inhibitor in the 6-wells. Forty-eight hours after transfection, the luciferase activity for each group was assessed using the Dual-Luciferase Kit (Promega). Renilla luciferase was used as the control. All experiments were repeated in triplicate.
| Statisticalanalysis
All statistical analyses and figure generation were performed using GraphPad Prism version 7.0 and Adobe Photoshop CC2015. Data were analysed using a 2-tailed Student t test. Statistical significance was ascribed at P < .05(*) or P < .01(**). Each experiment was independently repeated at least 3 times.
| RE SULTS
| TFPI2proteinlevelsareupregulatedinPE placentaltissues
The levels of TFPI2 in PE placental tissues and normal pregnancy placental tissues were analysed by western blotting. In contrast to normal pregnancy placental tissues, TFPI2 protein levels were noticeably upregulated in PE placental tissues ( Figure 1A ,B). We also performed immunohistochemistry assays to estimate TFPI2 protein levels, which were expressed predominantly in PE placental tissues rather than normal tissues, and primarily distributed in the cytoplasm ( Figure 1C ). The detailed clinical characteristics of the patients who met the criteria of the study are listed in Table 1 .
Emerging evidence has confirmed that miRNAs in cytoplasm mediate mRNA expression, thus further affecting cellular phenotype.
The protein levels of TFPI2 were upregulated in PE placental tissues and predominantly distributed in the cytoplasm, indicating that the level of TFPI2 might be regulated at a post-transcriptional level.
| MiR-616-3pisdownregulatedinPEplacenta tissuesanddirectlytargetsTFPI2
Based on bioinformatics analysis (included RNA22, RNAhybrid, Targetscan, miRMap and miRWalk.), we found that miR-616-3p was predicted to bind a region in the 3′ UTR of TFPI2 mRNA ( Figure 1E ).
Previous studies have confirmed that abnormally expressed miR-616 is involved in various biological processes in a multitude of diseases. [27] [28] [29] Ma et al 29 have also reported that miR-616 could induce androgen-independent growth of prostate cancer cells by regulating expression of TFPI2. Therefore, we postulate that TFPI2 was regulated by miR-616-3p in PE placental tissues. We conducted qRT-PCR to evaluate the expression of miR-616-3p in PE placental tissues and normal pregnancy placental tissues. As shown in Figure 1D , the expression level of miR-616-3p was significantly decreased in PE placental tissues compared with normal placental tissues. Since miR-616-3p might act as an essential regulator of TFPI2 in trophoblast cells, we chose miR-616-3p for further experiments to validate its specific binding to TFPI2.
In order to explore the direct interaction between miR-616-3p and TFPI2, various luciferase genes, including the 3′-UTR of TFPI2
and the mutated 3′-UTR sequence, were cloned and then cotransfected with miR-616-3p mimics and inhibitors in HTR-8/SVneo
and HEK-293T cell lines, respectively. Intriguingly, we found that the relative luciferase activity of the reporters of miR-616-3p mimics and 3′UTR of TFPI2 were significantly decreased compared with the control (Figure 2A,B) . In contrast, the relative luciferase activity of
The expression of tissue factor pathway inhibitor 2 (TFPI2) and miR-616-3p in human PE placenta tissues. A, Western blotting analysis of TFPI2 levels in PE placenta tissues compared with the normal (n = 6). B, Quantitative analysis of A; C, Images of HE staining and immunohistochemistry of the pregnancy placenta tissues. TFPI2 protein levels in placenta tissues as evaluated by immunohistochemistry. D, Relative levels of miR-616-3p in PE placenta tissues and the normal pregnancy placenta tissues (n = 16). The blue column indicates the upregulated expression of miR-616-3p, and red column indicates the downregulated level of miR-616-3p. E, The predicted base-pairing interaction between miR-616-3p and TFPI2 mRNA. NC represents the group of the normal pregnancy. Numbers are mean ± SD. **indicates P < .01; *indicates P < .05
the reporters of mutant 3′UTR of TFPI2 showed no difference after transfection with miR-616-3p mimics (Figure 2A,B) . 
| EffectsofTFPI2ontrophoblastcells proliferationandmigration
To investigate the biological effects of TFPI2 on trophoblast cells, we designed and synthesized the specific siRNAs and plasmids promoting overexpression to exogenously decrease/increase the expression of TFPI2 in HTR-8/SVneo cells. qRT-PCR and western blot analysis indicated that TFPI2 expression was significantly silenced/increased after transfection with specific siRNAs/overexpression plasmids in HTR-8/SVneo cells ( Figure 4A,B) . We then performed EdU and transwell assays to assess the function of TFPI2. As shown in Figure 4C ,E, silencing of TFPI2 expression significantly promoted cell proliferation and migration, while TFPI2 overexpression inhibited cell growth and migration ( Figure 4C-F) .
Zhou et al 30 have reported that TFPI2 decreased cell proliferation and migration, promoting cell apoptosis in JEG3 and BeWo cell lines. In parallel, rescue experiments also found that TFPI2
can rescue the inhibition effect of cell proliferation and migration of miR-616-3p ( Figure 5A,B) . Consequently, TFPI2 might act as an important suppressor in PE, while the aberrant expression of TFPI2 might induce the growth and migration of trophoblast cells involved in the pathogenesis of PE.
F I G U R E 5 miR-616-3p stimulates trophoblast cell growth and migration by inhibiting tissue factor pathway inhibitor 2 (TFPI2) in trophoblast cells. A, For cell growth analysis, MTT assays were performed to assess the cell viability for inhibitors miR-616-3p and si-TFPI2 co-transfected trophoblast cells. B, For cell migration analyses, migration was allowed to occur for 24 h. Quantitative analysis is below. Numbers are mean ± SD. **P < .01, *P < .05
| EffectsofmiR-616-3p-TFPI2pathwayonthe EMT-associatedmarkersinvitro
Previous studies have reported that epithelial-mesenchymal transition might be involved in cell migration and invasion. 31, 32 We further explored the function of the miR-616-3p-TFPI2-associated pathway in trophoblast cells. Epithelial and mesenchymal-induced markers, including E-cadherin, N-cadherin and vimentin, were tested with western blot assays. Our results
indicated that E-cadherin expression was higher after miR-616-3p upregulation or TFPI2 knockdown, and N-cadherin and vimentin expression was lower ( Figure 6A,B) . In contrast, the opposite occurred after transfection with miR-616-3p inhibitors or TFPI2 overexpresses ( Figure 6A ,B).
| D ISCUSS I ON
Recently, an increasing number of studies have indicated that miR- plasminogen activator, and the process of proteolysis, and prevent ECM degradation to affect cell migration and invasive capacity. 44, 45 Previous studies have revealed that TFPI2 acts as a suppressor gene in a variety of human diseases, including PE. [46] [47] [48] that an epigenetic mechanism might result in the pathogenesis of PE.
However, the role of TFPI2 in the pathogenesis of PE is still unknown.
In our study, we found that TFPI2 protein levels were significantly upregulated in PE placental tissues, while miR-616-3p transcriptional expression levels were clearly decreased. MiR-616-3p mRNA level was negatively correlated with TFPI2 protein level.
Bioinformatics analysis and a dual-luciferase activity assay have confirmed that miR-616-3p could bind to the 3′-UTR region of wildtype TFPI2 mRNA, but not the mutant construct. Also, miR-616-3p mimics resulted in downregulated TFPI2 protein levels, while miR- To sum up, our findings provide further evidence of an miR-616-3p/TFPI2-associated mechanism in PE, thus offering novel insights for the development of methods for latent diagnosis and therapeutic targets for PE. However, there are still many gaps in our current understanding of TFPI2 function and its biological mechanism in PE. Further studies are needed to elucidate a TFPI2-associated mechanism of PE. 
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